PALVELLA THERAPEUTICS INC(NASDAQ:PVLA) stock News

PVLA Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

3 days ago - By: Yahoo Finance - Mentions: WFC UBS MNDY CACI ...

Snap downgraded, Leidos upgraded: Wall Street's top analyst calls

3 days ago - By: Benzinga - Mentions: ALM ADAG INDV RAPP

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

5 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

5 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

5 days ago - By: Benzinga - Mentions: AVAV AIV WRD WVE ...

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

a month ago - By: Yahoo Finance

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

a month ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

a month ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

3 months ago - By: Yahoo Finance - Mentions: TIGO MASS VYEY AGL ...

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025

3 months ago - By: Yahoo Finance - Mentions: GRAL ADMA CP VYEY ...